Novavax’s COVID-19 vaccine approved for Canadians 18 and older – CBC

U.S. company struck deals with several governments early in 2020 but had encountered myriad issues

Feb 17, 2022

Novavax’s COVID-19 vaccine has been approved for use in Canadians age 18 and older by Health Canada.

The approval of the vaccine, known as Nuvaxovid, comes about 18 months after the federal government announced a deal to produce batches of it in Montreal.

Health Canada is recommending the interval for the two-dose vaccine to be at least 21 days based on evidence from clinical trials.

Chief Public Health Officer Dr. Theresa Tam said at a briefing Thursday the first Nuvaxovid delivery is expected in March, arriving from India’s Serum Institute. Federal officials said they weren’t able to provide any clarity on the size or schedule of the deliveries.

Trial data involving about 45,000 people in multiple countries suggests the vaccine is more than 90 per cent effective in preventing severe illness and death.

Read more: https://www.cbc.ca/news/health/novavax-health-canada-approval-1.6355106